mTOR regulation of lymphoid cells in immunity to pathogens

Frontiers in Immunology

Volumn 7, Issue MAY, 2016, Pages

  Keating, Rachael ^a   McGargill, Maureen Ann ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Immune differentiation; Immune regulation; Metabolism; mTOR; Pathogen

Indexed keywords

GAMMA INTERFERON; GRANZYME B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 4; INTERLEUKIN 7; L SELECTIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN BCL 6; PROTEIN KINASE C ALPHA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; S6 KINASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIBODY PRODUCTION; AUTOPHAGY; B LYMPHOCYTE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DEFENSE MECHANISM; EFFECTOR CELL; GENE EXPRESSION REGULATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS INFECTION;

EID: 84973560529     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00180     Document Type: Review

References (138)

1. Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol (2015) 15(10):599-614. doi:10.1038/nri3901
2. Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase a (IKKa). J Biol Chem (2014) 289(36):25227-40. doi:10.1074/jbc.M114.554881
3. Vander Haar E, Lee S-I, Bandhakavi S, Griffin TJ, Kim D-H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 9(3):316-23. doi:10.1038/ncb1547
4. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene (2006) 25(48):6416-22. doi:10.1038/sj.onc.1209888
5. Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J (2003) 372(Pt 2):555-66. doi:10.1042/bj20021266
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev (2004) 18(16):1926-45. doi:10.1101/gad.1212704
7. Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell (2011) 144(5):757-68. doi:10.1016/j.cell.2011.02.014
8. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11(6):859-71. doi:10.1016/j.devcel.2006.10.007
9. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol (2011) 31(12):2484-98. doi:10.1128/MCB.01061-10
10. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol (1996) 14:483-510. doi:10.1146/annurev.immunol.14.1.483
11. Sarbassov DD, Ali SM, Sengupta S, Sheen J-H, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 22(2):159-68. doi:10.1016/j.molcel.2006.03.029
12. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-101. doi:10.1126/science.1106148
13. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira S-M, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther (2009) 8(4):742-53. doi:10.1158/1535-7163.MCT-08-0668
14. Yang G, Murashige DS, Humphrey SJ, James DE. A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation. Cell Rep (2015) 12(6):937-43. doi:10.1016/j.celrep.2015.07.016
15. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene (2005) 24(53):7830-8. doi:10.1038/sj.onc.1208935
16. Spangle JM, Münger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 84(18):9398-407. doi:10.1128/JVI.00974-10
17. Moody CA, Scott RS, Amirghahari N, Nathan C-A, Young LS, Dawson CW, et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol (2005) 79(9):5499-506. doi:10.1128/JVI.79.9.5499-5506.2005
18. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, et al. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J (2005) 24(6):1211-21. doi:10.1038/sj.emboj.7600597
19. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 29(4):565-77. doi:10.1016/j.immuni.2008.08.012
20. Kudchodkar SB, Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase. J Virol (2004) 78(20):11030-9. doi:10.1128/JVI.78.20.11030-11039.2004
21. Jaramillo M, Gomez MA, Larsson O, Shio MT, Topisirovic I, Contreras I, et al. Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 9(4):331-41. doi:10.1016/j.chom.2011.03.008
22. Yakoub AM, Shukla D. Autophagy stimulation abrogates herpes simplex virus-1 infection. Sci Rep (2015) 5:9730. doi:10.1038/srep09730
23. Kim YC, Guan K-L. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 125(1):25-32. doi:10.1172/JCI73939
24. Tattoli I, Sorbara MT, Yang C, Tooze SA, Philpott DJ, Girardin SE. Listeria phospholipases subvert host autophagic defenses by stalling pre-autophagosomal structures. EMBO J (2013) 32(23):3066-78. doi:10.1038/emboj.2013.234
25. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell (2004) 119(6):753-66. doi:10.1016/j.cell.2004.11.038
26. Yakoub AM, Shukla D. Basal autophagy is required for herpes simplex virus-2 infection. Sci Rep (2015) 5:12985. doi:10.1038/srep12985
27. Tattoli I, Sorbara MT, Vuckovic D, Ling A, Soares F, Carneiro LAM, et al. Amino acid starvation induced by invasive bacterial pathogens triggers an innate host defense program. Cell Host Microbe (2012) 11(6):563-75. doi:10.1016/j.chom.2012.04.012
28. Zhu H, Han L, Shi X, Wang B, Huang H, Wang X, et al. Baicalin inhibits autophagy induced by influenza A virus H3N2. Antiviral Res (2015) 113:62-70. doi:10.1016/j.antiviral.2014.11.003
29. Ma J, Sun Q, Mi R, Zhang H. Avian influenza A virus H5N1 causes autophagy-mediated cell death through suppression of mTOR signaling. J Genet Genomics (2011) 38(11):533-7. doi:10.1016/j.jgg.2011.10.002
30. Datan E, Shirazian A, Benjamin S, Matassov D, Tinari A, Malorni W, et al. mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection. Virology (2014) 45(2-453):175-90. doi:10.1016/j.virol.2014.01.008
31. Marçais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol (2014) 15(8):749-57. doi:10.1038/ni.2936
32. Wai L-E, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation (2008) 85(1):145-9. doi:10.1097/01.tp.0000296817.28053.7b
33. Nandagopal N, Ali AK, Komal AK, Lee S-H. The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions. Front Immunol (2014) 5:187. doi:10.3389/fimmu.2014.00187
34. Eissens DN, Van Der Meer A, Van Cranenbroek B, Preijers FWMB, Joosten I. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant (2010) 10(9):1981-90. doi:10.1111/j.1600-6143.2010.03242.x
35. Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, et al. mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol (2014) 193(9):4477-84. doi:10.4049/jimmunol.1401558
36. Ripoli M, D'Aprile A, Quarato G, Sarasin-Filipowicz M, Gouttenoire J, Scrima R, et al. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. J Virol (2010) 84(1):647-60. doi:10.1128/JVI.00769-09
37. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 296(5571):1323-6. doi:10.1126/science.1070884
38. Sun JC, Ma A, Lanier LL. Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J Immunol (2009) 183(5):2911-4. doi:10.4049/jimmunol.0901872
39. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol (2013) 14(11):1146-54. doi:10.1038/ni.2731
40. Constantinides MG, Bendelac A. Transcriptional regulation of the NKT cell lineage. Curr Opin Immunol (2013) 25(2):161-7. doi:10.1016/j.coi.2013.01.003
41. Zhang L, Tschumi BO, Corgnac S, Rüegg MA, Hall MN, Mach J-P, et al. Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function. J Immunol (2014) 193(4):1759-65. doi:10.4049/jimmunol.1400769
42. Shin J, Wang S, Deng W, Wu J, Gao J, Zhong X-P. Mechanistic target of rapamycin complex 1 is critical for invariant natural killer T-cell development and effector function. Proc Natl Acad Sci U S A (2014) 111(8):E776-83. doi:10.1073/pnas.1315435111
43. Wei J, Yang K, Chi H. Cutting edge: discrete functions of mTOR signaling in invariant NKT cell development and NKT17 fate decision. J Immunol (2014) 193(9):4297-301. doi:10.4049/jimmunol.1402042
44. Prevot N, Pyaram K, Bischoff E, Sen JM, Powell JD, Chang C-H. Mammalian target of rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger. J Immunol (2015) 194(1):223-30. doi:10.4049/jimmunol.1401985
45. Huijts CM, Schneiders FL, Garcia-Vallejo JJ, Verheul HM, de Gruijl TD, van der Vliet HJ. mTOR inhibition per se induces nuclear localization of FOXP3 and conversion of invariant NKT (iNKT) cells into immunosuppressive regulatory iNKT cells. J Immunol (2015) 195(5):2038-45. doi:10.4049/jimmunol.1402710
46. Wu J, Shin J, Xie D, Wang H, Gao J, Zhong X-P. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. J Immunol (2014) 192(6):2643-50. doi:10.4049/jimmunol.1302076
47. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 195(5):617-24. doi:10.1084/jem.20011889
48. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine (2008) 26(15):1807-16. doi:10.1016/j.vaccine.2008.02.002
49. Youn H-J, Ko S-Y, Lee K-A, Ko H-J, Lee Y-S, Fujihashi K, et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine (2007) 25(28):5189-98. doi:10.1016/j.vaccine.2007.04.081
50. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer (2003) 106(2):236-43. doi:10.1002/ijc.11201
51. Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, Uezu K, et al. Critical role of Valpha14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. Eur J Immunol (2003) 33(12):3322-30. doi:10.1002/eji.200324254
52. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, Benhnia MR-E-I, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 7(9):978-86. doi:10.1038/ni1380
53. Mattner J, Savage PB, Leung P, Oertelt SS, Wang V, Trivedi O, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe (2008) 3(5):304-15. doi:10.1016/j.chom.2008.03.009
54. Delgoffe GM, Kole TP, Cotter RJ, Powell JD. Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Mol Immunol (2009) 46(13):2694-8. doi:10.1016/j.molimm.2009.05.185
55. Yamada T, Gierach K, Lee P-H, Wang X, Lacorazza HD. Cutting edge: expression of the transcription factor E74-like factor 4 is regulated by the mammalian target of rapamycin pathway in CD8+ T cells. J Immunol (2010) 185(7):3824-8. doi:10.4049/jimmunol.1000718
56. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol (2008) 84(4):949-57. doi:10.1189/jlb.0108024
57. Pollizzi KN, Patel CH, Sun I-H, Oh M-H, Waickman AT, Wen J, et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J Clin Invest (2015) 125(5):2090-108. doi:10.1172/JCI77746
58. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 209(13):2441-53. doi:10.1084/jem.20112607
59. Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL, Nikolich-Žugich J. Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol (2014) 193(2):757-63. doi:10.4049/jimmunol.1400188
60. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity (2011) 35(6):871-82. doi:10.1016/j.immuni.2011.09.021
61. Yao S, Buzo BF, Pham D, Jiang L, Taparowsky EJ, Kaplan MH, et al. Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation. Immunity (2013) 39(5):833-45. doi:10.1016/j.immuni.2013.10.007
62. Man K, Miasari M, Shi W, Xin A, Henstridge DC, Preston S, et al. The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. Nat Immunol (2013) 14(11):1155-65. doi:10.1038/ni.2710
63. Ito D, Nojima S, Nishide M, Okuno T, Takamatsu H, Kang S, et al. mTOR complex signaling through the SEMA4A-Plexin B2 axis is required for optimal activation and differentiation of CD8+ T cells. J Immunol (2015) 195(3):934-43. doi:10.4049/jimmunol.1403038
64. Finlay D, Cantrell D. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann N Y Acad Sci (2010) 1183:149-57. doi:10.1111/j.1749-6632.2009.05134.x
65. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 9(5):513-21. doi:10.1038/ni.1603
66. van der Windt GJW, Everts B, Chang C-H, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2012) 36(1):68-78. doi:10.1016/j.immuni.2011.12.007
67. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 460(7251):108-12. doi:10.1038/nature08155
68. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang L-S, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460(7251):103-7. doi:10.1038/nature08097
69. He S, Kato K, Jiang J, Wahl DR, Mineishi S, Fisher EM, et al. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS One (2011) 6(5):e20107. doi:10.1371/journal.pone.0020107
70. Shrestha S, Yang K, Wei J, Karmaus PWF, Neale G, Chi H. Tsc1 promotes the differentiation of memory CD8+ T cells via orchestrating the transcriptional and metabolic programs. Proc Natl Acad Sci U S A (2014) 111(41):14858-63. doi:10.1073/pnas.1404264111
71. Li Q, Rao R, Vazzana J, Goedegebuure P, Odunsi K, Gillanders W, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol (2012) 188(7):3080-7. doi:10.4049/jimmunol.1103365
72. Stoycheva D, Deiser K, Stärck L, Nishanth G, Schlüter D, Uckert W, et al. IFN-κ regulates CD8+ memory T cell differentiation and survival in response to weak, but not strong, TCR signals. J Immunol (2015) 194(2):553-9. doi:10.4049/jimmunol.1402058
73. Cukalac T, Chadderton J, Zeng W, Cullen JG, Kan WT, Doherty PC, et al. The influenza virus-specific CTL immunodominance hierarchy in mice is determined by the relative frequency of high-avidity T cells. J Immunol (2014) 192(9):4061-8. doi:10.4049/jimmunol.1301403
74. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 32(1):67-78. doi:10.1016/j.immuni.2009.10.010
75. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, et al. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 34(4):541-53. doi:10.1016/j.immuni.2011.04.006
76. Garcia K, Sun Z, Mattson E, Li L, Smyth K, Xiao Z. IL-12 is required for mTOR regulation of memory CTLs during viral infection. Genes Immun (2014) 15(6):413-23. doi:10.1038/gene.2014.33
77. Mehlhop-Williams ER, Bevan MJ. Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation. J Exp Med (2014) 211(2):345-56. doi:10.1084/jem.20131271
78. Richer MJ, Pewe LL, Hancox LS, Hartwig SM, Varga SM, Harty JT. Inflammatory IL-15 is required for optimal memory T cell responses. J Clin Invest (2015) 125(9):3477-90. doi:10.1172/JCI81261
79. Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity (2014) 41(5):802-14. doi:10.1016/j.immuni.2014.10.013
80. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12(6):492-9. doi:10.1038/ni.2035
81. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrançois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity (2004) 20(5):551-62. doi:10.1016/S1074-7613(04)00103-7
82. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med (2010) 207(3):553-64. doi:10.1084/jem.20090858
83. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science (2014) 346(6205):98-101. doi:10.1126/science.1254536
84. Sowell RT, Rogozinska M, Nelson CE, Vezys V, Marzo AL. Cutting edge: generation of effector cells that localize to mucosal tissues and form resident memory CD8 T cells is controlled by mTOR. J Immunol (2014) 193(5):2067-71. doi:10.4049/jimmunol.1400074
85. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol (2006) 177(5):2888-98. doi:10.4049/?jimmunol.177.5.2888
86. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, Dutton RW, et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest (2012) 122(8):2847-56. doi:10.1172/JCI63689
87. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol (2012) 30:39-68. doi:10.1146/annurev-immunol-020711-075024
88. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 28:445-89. doi:10.1146/annurev-immunol-030409-101212
89. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 30(6):832-44. doi:10.1016/j.immuni.2009.04.014
90. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 33(3):301-11. doi:10.1016/j.immuni.2010.09.002
91. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 12(4):295-303. doi:10.1038/ni.2005
92. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR?. Cell Rep (2012) 1(4):360-73. doi:10.1016/j.celrep.2012.02.007
93. Yang K, Shrestha S, Zeng H, Karmaus PWF, Neale G, Vogel P, et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity (2013) 39(6):1043-56. doi:10.1016/j.immuni.2013.09.015
94. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity (2010) 32(6):743-53. doi:10.1016/j.immuni.2010.06.002
95. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 186(6):3299-303. doi:10.4049/jimmunol.1003613
96. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208(7):1367-76. doi:10.1084/jem.20110278
97. Dang EV, Barbi J, Yang H-Y, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146(5):772-84. doi:10.1016/j.cell.2011.07.033
98. Sanchez AM, Yang Y. The role of natural regulatory T cells in infection. Immunol Res (2011) 49(1-3):124-34. doi:10.1007/s12026-010-8176-8
99. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol (2005) 6(4):331-7. doi:10.1038/ni1179
100. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 212:8-27. doi:10.1111/j.0105-2896.2006.00427.x
101. Battaglia M, Stabilini A, Roncarolo M-G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105(12):4743-8. doi:10.1182/blood-2004-10-3932
102. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo M-G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 177(12):8338-47. doi:10.4049/?jimmunol.177.12.8338
103. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 205(3):565-74. doi:10.1084/jem.20071477
104. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 7(7):1722-32. doi:10.1111/j.1600-6143.2007.01842.x
105. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol (2006) 177(2):944-9. doi:10.4049/?jimmunol.177.2.944
106. Kopf H, de la Rosa GM, Howard OMZ, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 7(13):1819-24. doi:10.1016/j.intimp.2007.08.027
107. Yurchenko E, Shio MT, Huang TC, Da Silva Martins M, Szyf M, Levings MK, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLoS One (2012) 7(4):e35572. doi:10.1371/journal.pone.0035572
108. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 32(1):54-66. doi:10.1016/j.immuni.2009.12.003
109. Gabryšová L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A. Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol (2011) 41(5):1242-8. doi:10.1002/eji.201041073
110. Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol (2010) 11(11):1047-56. doi:10.1038/ni.1939
111. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 499(7459):485-90. doi:10.1038/nature12297
112. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 29:621-63. doi:10.1146/annurev-immunol-031210-101400
113. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 325(5943):1006-10. doi:10.1126/science.1175870
114. Poholek AC, Hansen K, Hernandez SG, Eto D, Chandele A, Weinstein JS, et al. In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol (2010) 185(1):313-26. doi:10.4049/jimmunol.0904023
115. Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity (2011) 34(6):932-46. doi:10.1016/j.immuni.2011.03.023
116. Choi YS, Yang JA, Yusuf I, Johnston RJ, Greenbaum J, Peters B, et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol (2013) 190(8):4014-26. doi:10.4049/jimmunol.1202963
117. Ray JP, Marshall HD, Laidlaw BJ, Staron MM, Kaech SM, Craft J. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity (2014) 40(3):367-77. doi:10.1016/j.immuni.2014.02.005
118. Ray JP, Staron MM, Shyer JA, Ho P-C, Marshall HD, Gray SM, et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T Cells. Immunity (2015) 43(4):690-702. doi:10.1016/j.immuni.2015.08.017
119. Pepper M, Pagán AJ, Igyártó BZ, Taylor JJ, Jenkins MK. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. Immunity (2011) 35(4):583-95. doi:10.1016/j.immuni.2011.09.009
120. Choi YS, Eto D, Yang JA, Lao C, Crotty S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol (2013) 190(7):3049-53. doi:10.4049/jimmunol.1203032
121. Ballesteros-Tato A, León B, Graf BA, Moquin A, Adams PS, Lund FE, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity (2012) 36(5):847-56. doi:10.1016/j.immuni.2012.02.012
122. Marshall HD, Ray JP, Laidlaw BJ, Zhang N, Gawande D, Staron MM, et al. The transforming growth factor beta signaling pathway is critical for the formation of CD4 T follicular helper cells and isotype-switched antibody responses in the lung mucosa. eLife (2015) 4:e04851. doi:10.7554/eLife.04851
123. Oestreich KJ, Read KA, Gilbertson SE, Hough KP, McDonald PW, Krishnamoorthy V, et al. Bcl-6 directly represses the gene program of the glycolysis pathway. Nat Immunol (2014) 15(10):957-64. doi:10.1038/ni.2985
124. Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood (2011) 117(4):1228-38. doi:10.1182/blood-2010-05-287821
125. Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, et al. B cell-specific deficiencies in mTOR limit humoral immune responses. J Immunol (2013) 191(4):1692-703. doi:10.4049/jimmunol.1201767
126. Lazorchak AS, Liu D, Facchinetti V, Di Lorenzo A, Sessa WC, Schatz DG, et al. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell (2010) 39(3):433-43. doi:10.1016/j.molcel.2010.07.031
127. Lee K, Heffington L, Jellusova J, Nam KT, Raybuck A, Cho SH, et al. Requirement for Rictor in homeostasis and function of mature B lymphoid cells. Blood (2013) 122(14):2369-79. doi:10.1182/blood-2013-01-477505
128. Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. Eur J Immunol (2011) 41(8):2390-6. doi:10.1002/eji.201041336
129. Ci X, Kuraoka M, Wang H, Carico Z, Hopper K, Shin J, et al. TSC1 promotes B cell maturation but is dispensable for germinal center formation. PLoS One (2015) 10(5):e0127527. doi:10.1371/journal.pone.0127527
130. Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol (2007) 37(10):2923-36. doi:10.1002/eji.200737281
131. Donahue AC, Fruman DA. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J Immunol (2003) 170(12):5851-60
132. Sakata A, Kuwahara K, Ohmura T, Inui S, Sakaguchi N. Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett (1999) 68(2-3):301-9. doi:10.1016/S0165-2478(99)00053-X
133. Wicker LS, Boltz RC Jr, Matt V, Nichols EA, Peterson LB, Sigal NH. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol (1990) 20(10):2277-83. doi:10.1002/eji.1830201017
134. Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology (1991) 72(4):544-9
135. Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol (1994) 156(2):493-507. doi:10.1006/cimm.1994.1193
136. Zeng Q, Zhang H, Qin J, Xu Z, Gui L, Liu B, et al. Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Cell Mol Life Sci (2015) 72(24):4867-84. doi:10.1007/s00018-015-1976-1
137. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol (2013) 14(12):1266-76. doi:10.1038/ni.2741
138. Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A (2014) 111(47):E5076-85. doi:10.1073/pnas.1407104111